Evidence map›Paper›PMID 42016705›Full record

ArticleFrontiers in oncology2026

Predicting recurrence of prostate cancer after radical treatment using AI models based on PET/CT radiomics: a dual-center study.

Zhanxiong Yi, Weichun Li, Yueyang Lou, Qinbing Zhou

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhanxiong YiDepartment of Nuclear Medicine, Dongyang People's Hospital, Dongyang, Zhejiang, China.
Weichun LiDepartment of Nuclear Medicine, Dongyang People's Hospital, Dongyang, Zhejiang, China.
Yueyang LouDepartment of Nuclear Medicine, Dongyang People's Hospital, Dongyang, Zhejiang, China.
Qinbing ZhouDepartment of Nuclear Medicine, Quzhou People's Hospital, Quzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predicting prostate cancer (PCa) recurrence after radical treatment is crucial for personalised adjuvant therapy. This study aimed to compare different algorithms in order to select the best model for predicting recurrence. Therefore, a retrospective cohort analysis was conducted on 72 patients with radical prostate cancer, including 39 patients with biochemical recurrence and 33 patients without recurrence. We extracted features from imaging data, construct and evaluate 10 machine learning models and 8 deep learning models. Model performance was assessed using the area under the curve (AUC), accuracy, sensitivity, specificity, precision, 10-fold cross-validation AUC, and F1-score. In addition, the feature importance was analysed. Among all models, the MLP-Mixed-Act model exhibited superior performance in all evaluation indicators (AUC = 0.910, accuracy =0.819, sensitivity =0.744, specificity =0.909, precision =0.912, F1 = 0.817), thereby indicating its strong predictive ability and clinical application potential. This study provides a theoretical basis for the development of preventive and non-invasive recurrence prediction tools. Especially in the context of valuing the tumor microenvironment, accurate recurrence prediction can effectively help select immunotherapy strategies, improve treatment efficacy and prognosis, and support for personalized treatment of PCa.

Indexed as

deep learningpositron emission tomography/computed tomographyprostate cancerradiomicsrecurrence prediction

Identifiers

PMID42016705
PMCPMC13093974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.